Cancer is a leading cause of death worldwide with increased mortality due to disease reoccurrence, tumor metastasis, and drug resistance.
TEX CORE is an innovative technology platform that uses clinically validatedtexaphyrin to develop novel tumor localizing designer compounds to treat different types of cancers.
Texaphyrin is an expanded porphyrin that forms stable complexes with metal cations that are MRI contrast agents with oncology activity. The texaphyrin in TEX CORE is known to localize to both primary and metastatic tumor sites with high specificity.
Texaphyrin has been clinically validated in Phase III trials to localize to solid tumors and is MRI detectable.
Note: InnovoTEX is developing its TEX CORE platform that utilizes the tumor localizing and well-tolerated small molecule, texaphyrin, as the basis for a series of conjugates designed to treat both drug-sensitive and drug-resistant solid tumors.
OxaliTEX is being developed to treat platinum-resistant ovarian cancer,
the #1 cause of gynecological deaths globally.
OxaliTEX targets and infiltrates cancer cells to overcome key resistance mechanisms:
AuraTEX is being developed to treat colon cancer, non-small cell lung cancer (NSCLC), and castrate-resistant prostate cancer and urogenital neoplasms.
AuraTEX activates the immune system to help fight the growth and spread of cancer.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.